To evaluate potential use of our previous findings for clinical purposes, we performed a pilot study where we examined the expression of FREM2 and SPRY1 at the proteomic and transcriptomic levels in different grades of gliomas and nonmalignant brain-tissue samples. This evidence concerns the gene SPRY1 and central nervous system cancer.